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ABSTRACT
Tuberculosis  causes  more than two million deaths  per  year.  Faced  with this global threat  it  is  crucial  to better 
understand the physiology of the causative organism,  Mycobacterium Tuberculosis, in order to develop efficient 
therapeutic strategies. PKnB from Mycobacterium tuberculosis is a crucial receptor-like protein kinase involved in 
signal transduction. M. tuberculosis PKnB is a trans-membrane Ser/Thr protein kinase (STPK) highly conserved in 
Gram-positive bacteria and apparently essential for Mycobacterial viability.  We have attempted with the help of 
virtual screening and docking approach to expound the extent of specificity of protein kinase B towards different  
classes  of Thiadiazoles  (an anti-tubercular  agent).   The selected Thiadiazoles were selected on the basis of the 
structural specificity to the enzyme towards its substrate and inhibitors. Total number of Thiadiazoles were 5000 in 
number with the minimum binding energy of -10.46 kcal/mol with 10 molecules showing hydrogen bonds with the  
active site residue. The protein kinase B peptide contains two types of structural elements (Valine 95, Arginine 97)  
and basic residue ring constituted of glycine rich residue. The structure of the protein-ligand complex reveals that  
Thiadiazoles  partially  occupies  the  adenine-binding  pocket  in  PKnB,  providing a  framework  for  the  design  of 
compounds with potential therapeutic applications. The study provides hints for the future design of new derivatives 
with higher potency and specificity.
Keywords: Protein Kinase PKnB, Mycobacterium Tuberculosis, 1, 3, 4- Thiadiazdole, Drug Discovery, Molecular 
Docking, AutoDock4. 
INTRODUCTION
The knack of  Mycobacterium tuberculosis, pathogen 
liable for Tuberculosis (TB), to adapt to the 
changing environmental conditions requires 
an efficient way of sensing and transducing 
extracellular  signals  [1].  One  of  the 
mechanisms used in Mycobacteria to assure 
a tight regulation of cell growth and division 
involves  the  reversible  phosphorylation  on 
serine/threonine residues, a well-established 
process for eukaryotic signaling networks [2]. 
M.  tuberculosis PknB is  a  trans-membrane 
Ser/Thr  protein  kinase  (STPK)  highly 
conserved  in  Gram-positive  bacteria  and 
apparently  essential  for  mycobacterial 
viability  [3].  The  crystal  structure  of  the 
kinase domain of PknB in complex with an 
ATP analogue  [4] and  [5] showed a  striking 
conservation  of  both  protein  fold  and 
catalytic mechanism between eukaryotic and 
prokaryotic  STPKs.  Earlier  it  was  shown 
that  PKnB  is  regulated  by  auto-
phosphorylation  and  dephosphorylation  by 
the Ser/Thr protein phosphatase [6] and [7] and 
recent  work  showed  that  PKnB  is 
predominantly expressed during exponential 
growth,  where  its  over  expression  causes 
morphological changes linked to defects  in 
cell wall synthesis and cell division [8].
Aberrant  kinase  activity  is  implicated  in  numerous 
human diseases and, not surprisingly, protein kinases 
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represent today one of the most important groups of 
drug  targets  [9] and  [10].  Here  we  report  that 
thiadiazole,  a  compound  reported  as  anti-microbial 
[10-13] and  anti-tubercular  agent  [14-18] is  a  PKnB 
inhibitor  capable  of  preventing  mycobacterial  cell 
growth,  suggesting  that  bacterial  kinases  may  also 
represent  a  potential  target  for  drug  design  and 
derivatives  of  Thiazdiazoles  exhibit  a  property  of 
inhibiting mycobacterial growth. The structure of the 
protein-ligand  complex  shows  that  Thiadiazole 
derivatives bound to the structural element (VAL 95) 
of PKnB from MTB  partially occupies the adenine-
binding pocket in PKnB and  is an ATP-competitive 
inhibitor of PKnB and suggests a mode of regulation 
of protein kinases in mycobacteria.
2. MATERIALS AND METHODS
2.1. In silico screening
5000 compounds from different  chemical  databases 
were screened, including the PubChem & ChemBank 
compound  datbases.  They  were  docked  into  the 
nucleotide-binding  pocket  comprising  of  VAL 
95(active site residue) of the  M. tuberculosis PKnB 
structure  (PDB  ID.  2fum  [1])  using  the  program 
AutoDock4 [19].
2.2 Substrate selection
4000 structures  most 2D-similar to Thiadiazole and 
1,  3,  4-  Thiadiazole  (Fig  1)  were  chosen 
based  on  screening  from  the 
ChemBank[20] .The  chosen  ligands  have 
conformational  stability  and  structural 
diversity in relation to the bound ligands to 
the  crystal  structure.  The  ligand  structures 
used  in  docking  were  obtained  from 
ChemBank compound database  [21]. Ligands 
were  identified as  per  the pharmacokinetic 
parameter  and  solubility.  The  molecules 
were  searched  by  similarity  search 
compound  collection,  by  similarity  to  a 
structure  (may be specified  via a  SMILES 
string,  or  drawn  with  JME  Molecular 
Editor). The molecules were screened where 
the structure is similar to C1=NN=CS1 (of 
Thiadiazole from  PubChem)  using  the 
Tanimoto metric with a distance of .8.
The active site i.e. VAL 95 in the protein interacts 
with  ligands  of  the  substrate  and  gives  rise  to  the 
catalytic  activity  to  test  ligands  that  helps  in 
determining the binding pattern of the ligands to the 
active site of PKnB (PDB; 2FUM). 
 
 
Fig 1: Structure of 1, 3, 4 Thiadiazole
In  Last,  1000  molecules,  based  on  structural 
similarity of 1, 3, 4-  Thiadiazole was selected from 
PubChem and then docking was performed.
2.3. Docking setup
Docking was performed using Autodock 4,  a novel 
and robust  automated docking method that  predicts 
the  bound  conformations  of  flexible  ligands  to 
macromolecular  targets.  Interestingly,  this  method 
applies  a  Lamarckian  model  of  genetics,  in  which 
environmental  adaptations  of  an  individual’s 
phenotype are  reverse  transcribed  into its  genotype 
and become heritable traits (sic). We have considered 
Lamarckian genetic algorithm, search method which 
can  handle  ligands  with  more  degrees  of  freedom 
than  the  Monte  Carlo  simulated  annealing  and 
traditional  genetic algorithm method used in earlier 
versions of AUTODOCK, and that  the Lamarckian 
genetic algorithm is the most efficient, reliable, and 
successful. AutoDock 4, combines energy evaluation 
through grids of affinity potential employing various 
search algorithms to find the suitable binding position 
for a ligand on a given protein (Morris et al., 1998). 
While  docking,  polar  hydrogen’s  were  added  to 
ligands  using  the  hydrogen’s  module  in  Autodock 
tool  and  thereafter,  Kollman  united  atom  partial 
charges  were  assigned  (La  Motta  et al.,  2007). 
Docking of PKnB to ligands was carried out using 
LGA with standard docking protocol on the basis a 
population size of 150 randomly placed individuals; a 
maximum number of 2.5 * 107 energy evaluations, a 
mutation rate of 0.02, a crossover rate of 0.80 and an 
elitism value of 1. Fifteen independent docking runs 
were  carried  out  for  each  ligand  and  results  were 
clustered according  to the 1.0 Ǻ rmsd criteria.  The 
grid maps representing the proteins were calculated 
using auto grid and  grid size  was  set  to  60*60*60 
points with grid spacing of 0.375 Ǻ. 
RESULTS AND DISCUSSION
Docking of 5000 molecules was carried out for PKnB 
which  showed  a  binding  energy  of  -10.46. The 
docking results were interpreted according to the .pdb 
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file. We have used the co-ordinates of the minimum 
energy run created in the .dlg which was determined 
using the rmsd table created in the .dlg file itself (Fig-
2).
Fig 2: Rmsd table of the DLG file generated
On docking of 5000 molecules with VAL 95 (active 
site)  residue  according  to  the  minimum  binding 
energy generated by AutoDock 4 the results shows 
that 5 molecules showed best results (Table-1).
2,5-bis[(4-
bromobenzyl)thio]-1,3,4-
thiadiazole
N- {5- [(2- fluorobenzyl) 
thio]- 1,3,4- thiadiazol- 
2- yl}- 2- (2- 
methylphenoxy) 
acetamide
N- (5- methyl- 1,3,4- 
thiadiazol- 2- yl) - 2- 
(9H- xanthen- 9- yl) 
acetamide
N- (2- fluorophenyl) - 5- 
{[2- (3- methylpiperidin- 
1- yl) - 2- 
oxoethyl]thio}- 1,3,4- 
thiadiazol- 2- amine
N- {5- [(benzylthio) 
methyl]- 1,3,4- 
thiadiazol- 2- yl}- 4- 
fluorobenzamide
2- (4- benzylpiperazin- 
1- yl) - N- (5- ethyl- 
1,3,4- thiadiazol- 2- yl) 
acetamide
9- {3- [(5- methyl- 1,3,4- 
thiadiazol- 2- yl) 
thio]propanoyl}- 2,3,4,9- 
tetrahydro- 1H- 
carbazole
5- {[2- (9H- carbazol- 9- 
yl) - 2- oxoethyl]thio}- 
1,3,4- thiadiazol- 2- 
amine
3- (2,3- dihydro- 1,4- 
benzodioxin- 2- yl) - 6- 
pyridin- 3- 
yl[1,2,4]triazolo[3,4- b]
[1,3,4]thiadiazole
9- {3- [(5- methyl- 1,3,4- 
thiadiazol- 2- yl) 
thio]propanoyl}- 9H- 
carbazole
Table 1- Molecules showed best docking results
The  molecules  that  gave  best  binding  energies 
(Table-2)  are  then  looked for  Lipinski’s  Rule  of  5 
parameter and the results showed that all 10 of them 
follow  Lipinski’s  rule  of  5.  After  that  they  were 
tested for structure analysis by the visualization tool. 
The coordinate of the docked protein along with the 
ligand was visualized using UCSF chimera [22] within 
6.5 Ǻ region. The protein-ligand complex showed H 
-bond with the active site residue (Table- 3).
Our  result  indicates  that  the  ligand  have  varied 
binding pattern with substrate binding site i.e. VAL-
95  along  with  various  other  active  sites.  10 
compounds demonstrate better binding patterns with 
protein in terms of hydrogen bonds with the various 
residues of the protein. The docked confirmation of 
all the ligands is shown in Fig 2.
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
11
.6
13
6.
1 
: P
os
te
d 
22
 J
ul
 2
01
1
In  summary,  based  on  the  molecular  docking  we 
found that compounds  from Table 1  as of  structure 
similarity of 1 3 4 Thiadiazole showed better binding 
affinities with the active site pocket (comprising of 
VAL-95) of the PKnB enzyme(Fig- 3a, b, c, d, e). Fig 
4 shows the docked confirmation of 2,5-bis[(4-bromo 
benzyl)thio]-1,3,4-thiadiazole.  Our  study  gives  an 
idea  about  the  interaction  between  the  active  site 
residues and the substrate which is explained on the 
basis of size & hydrophobicity of the binding pocket. 
The molecules that showed less binding energy and 
showed better  interactions  with  protein  are  not  yet 
tested in the laboratory and the autoflourescence data 
for these molecules is not available. The extent of the 
work  stretches  to  the  in-silico  approach  for 
determining the binding mode. Further there is need 
to  generate  in  vitro  and  in-vivo  activity  of  the 
generated  data  to  synthesize  and  test  so  to  design 
drugs with better specificity and metabolism. 
ACKNOWLEDGMENT
We are  grateful  to  acknowledge the entire  team of 
BioDiscovery-Solutions  for  future,  Agra  for 
providing  the  facilities  and  resources.  We are  also 
thankful to Dr. S. Bhadauria, Dr D Sankari, Dr Arshi 
Naqvi  and  Mr  Ajay  Kumar  Singh  for  useful 
discussions on manuscript preparation.
FIGURES
Fig:  2-  Docked  conformation  of  all  the  ligands, 
visualized by Chimera
Fig: 2a- H-Bond with active site residue
Fig: 2b- H-Bond with active site residue
Fig: 2c- H-Bond with active site residue
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Fig: 2d- H-Bond with active site residue
Fig: 2e- H-Bond with active site residue
Fig: 4- Docked confirmation of 2,5-bis[(4-bromo benzyl)thio]-1,3,4-thiadiazole
TABLES
TABLE- 2 BINDING ENERGIES OF TOP 10 MOLECULES
S. No. COMPOUNDS NAME BINDING ENERGY
(kcal.mol) 
(MIN)
BINDING ENERGY
(kcal.mol) 
(MAX)
1. 2,5-bis[(4-bromobenzyl)thio]-1,3,4-
thiadiazole
-10.46 -7.79
2. N-  {5-  [(2-  fluorobenzyl)  thio]-  1,3,4- 
thiadiazol-  2-  yl}-  2-  (2-  methylphenoxy) 
acetamide
-9.57 -7.43
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3. N-  (5-  methyl-  1,3,4-  thiadiazol-  2-  yl)  -  2- 
(9H- xanthen- 9- yl) acetamide
-9.35 -9.01
4. N-  (2-  fluorophenyl)  -  5-  {[2-  (3- 
methylpiperidin-  1-  yl)  -  2-  oxoethyl]thio}- 
1,3,4- thiadiazol- 2- amine
-9.28 6.34
5. N-  {5-  [(benzylthio)  methyl]-  1,3,4- 
thiadiazol- 2- yl}- 4- fluorobenzamide
-9.00 -8.88
6. 2- (4- benzylpiperazin- 1- yl) - N- (5- ethyl- 
1,3,4- thiadiazol- 2- yl) acetamide
-9.00 -8.02
7. 9-  {3-  [(5-  methyl-  1,3,4-  thiadiazol-  2-  yl) 
thio]propanoyl}-  2,3,4,9-  tetrahydro-  1H- 
carbazole
-8.96 -6.53
8. 5-  {[2-  (9H-  carbazol-  9-  yl)  -  2- 
oxoethyl]thio}- 1,3,4- thiadiazol- 2- amine
-8.88 -5.22
9. 3- (2,3- dihydro- 1,4- benzodioxin- 2- yl) - 6- 
pyridin-  3-  yl[1,2,4]triazolo[3,4-  b]
[1,3,4]thiadiazole
-8.86 -7.46
10. 9-  {3-  [(5-  methyl-  1,3,4-  thiadiazol-  2-  yl) 
thio]propanoyl}- 9H- carbazole
-8.79 -8.11
TABLE- 3 H- BOND INFORMATION OF TOP 10 MOLECULES
COMPONDS MIN MAX HYDROGEN 
BONDS
BLUE-ORGANGE
2,5-bis[(4-bromobenzyl)thio]-1,3,4-
thiadiazole
-10.46 -7.79 1, 3
N- {5- [(2- fluorobenzyl) thio]- 1,3,4- 
thiadiazol- 2- yl}- 2- (2- methylphenoxy) 
acetamide
-9.57 -7.43 2, 1
N- (5- methyl- 1,3,4- thiadiazol- 2- yl) - 2- 
(9H- xanthen- 9- yl) acetamide
-9.35 -9.01 0, 2
N- (2- fluorophenyl) - 5- {[2- (3- 
methylpiperidin- 1- yl) - 2- oxoethyl]thio}- 
1,3,4- thiadiazol- 2- amine
-9.28 6.34 1, 1
N- {5- [(benzylthio) methyl]- 1,3,4- -9.00 -8.88 2, 1
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thiadiazol- 2- yl}- 4- fluorobenzamide
2- (4- benzylpiperazin- 1- yl) - N- (5- ethyl- 
1,3,4- thiadiazol- 2- yl) acetamide
-9.00 -8.02 2, 3
9- {3- [(5- methyl- 1,3,4- thiadiazol- 2- yl) 
thio]propanoyl}- 2,3,4,9- tetrahydro- 1H- 
carbazole
-8.96 -6.53 2, 4
5- {[2- (9H- carbazol- 9- yl) - 2- 
oxoethyl]thio}- 1,3,4- thiadiazol- 2- amine
-8.88 -5.22 3,2
3- (2,3- dihydro- 1,4- benzodioxin- 2- yl) - 6- 
pyridin- 3- yl[1,2,4]triazolo[3,4- b]
[1,3,4]thiadiazole
-8.86 -7.46 1,2
9- {3- [(5- methyl- 1,3,4- thiadiazol- 2- yl) 
thio]propanoyl}- 9H- carbazole
-8.79 -8.11 2, 0
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